SAB Biotherapeutics (SABS) Short Interest Ratio & Short Volume $3.88 +0.62 (+19.02%) (As of 11/1/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SAB Biotherapeutics Short Interest DataSAB Biotherapeutics (SABS) has a short interest of 79,800 shares, representing 1.07% of the float (the number of shares available for trading by the public). This marks a 92.29% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.6, indicating that it would take 1.6 days of the average trading volume of 28,427 shares to cover all short positions.Current Short Interest79,800 sharesPrevious Short Interest41,500 sharesChange Vs. Previous Month+92.29%Dollar Volume Sold Short$193,116.00Short Interest Ratio1.6 Days to CoverLast Record DateOctober 15, 2024Outstanding Shares9,230,000 sharesFloat Size7,490,000 sharesShort Percent of Float1.07%Today's Trading Volume206,788 sharesAverage Trading Volume28,427 sharesToday's Volume Vs. Average727% Short Selling SAB Biotherapeutics? Sign up to receive the latest short interest report for SAB Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSABS Short Interest Over TimeSABS Days to Cover Over TimeSABS Percentage of Float Shorted Over Time Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here SAB Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/15/202479,800 shares $193,116.00 +92.3%1.1%1.6 $2.42 9/30/202441,500 shares $112,050.00 +37.4%0.6%2.3 $2.70 9/15/202430,200 shares $84,258.00 -12.7%0.4%1.9 $2.79 8/31/202434,600 shares $101,724.00 +32.1%0.5%3.7 $2.94 8/15/202426,200 shares $58,950.00 -8.1%0.4%2.6 $2.25 7/31/202428,500 shares $79,093.20 +8.0%0.4%1.7 $2.78 Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/15/202426,400 shares $76,560.00 -17.0%0.4%1.6 $2.90 6/30/202431,800 shares $98,580.00 -7.0%0.4%2 $3.10 6/15/202434,200 shares $107,730.00 +0.9%0.5%2.1 $3.15 5/31/202433,900 shares $89,496.00 +50.7%0.5%1.9 $2.64 5/15/202422,500 shares $88,425.00 No Change0.3%1.2 $3.93 4/30/202422,500 shares $96,525.00 -12.1%0.3%1.7 $4.29 4/15/202425,600 shares $111,616.00 -11.4%0.3%1.8 $4.36 3/31/202428,900 shares $131,206.00 +38.3%0.4%1.7 $4.54 3/15/202420,900 shares $115,368.00 -15.0%0.3%1.1 $5.52 2/29/202424,600 shares $109,716.00 -37.1%0.3%1.5 $4.46 2/15/202439,100 shares $217,005.00 +17.8%0.5%2.9 $5.55 1/31/202433,200 shares $199,200.00 +90.8%0.4%2.8 $6.00 1/15/202417,400 shares $104,052.00 -2.8%0.2%1.5 $5.98 12/31/202317,900 shares $12,306.25 -91.4%N/A2.1 $0.69 12/15/2023207,600 shares $153,291.84 -11.2%0.3%3 $0.74 11/30/2023233,700 shares $227,156.40 +1.7%0.7%3.8 $0.97 11/15/2023229,800 shares $209,118.00 -12.1%0.6%4.4 $0.91 10/31/2023261,400 shares $261,373.86 -2.2%0.7%5.2 $1.00 10/15/2023267,200 shares $187,574.40 -2.8%0.7%6.4 $0.70 9/30/2023274,900 shares $173,187.00 -10.3%0.7%7.4 $0.63 9/15/2023306,500 shares $199,225.00 -17.5%0.8%8.5 $0.65 8/31/2023371,600 shares $267,552.00 +8.8%1.0%7 $0.72 8/15/2023341,500 shares $269,785.00 -12.3%0.9%5.9 $0.79 7/31/2023389,300 shares $315,333.00 -12.4%1.1%4.7 $0.81 7/15/2023444,400 shares $385,472.56 -4.1%1.3%1.6 $0.87 6/30/2023463,200 shares $384,456.00 +27.2%1.3%0.3 $0.83 6/15/2023364,300 shares $329,691.50 -14.9%1.0%0.3 $0.91 5/31/2023428,100 shares $381,009.00 -35.7%1.2%0.3 $0.89 5/15/2023665,400 shares $585,552.00 +28.3%1.9%0.5 $0.88 4/30/2023518,600 shares $465,858.38 +287.6%1.5%0.4 $0.90 4/15/2023133,800 shares $97,071.90 -3.2%0.4%0.1 $0.73 3/31/2023138,200 shares $60,808.00 -30.1%0.4%3.4 $0.44 3/15/2023197,800 shares $100,878.00 +17.5%0.6%4.3 $0.51 2/28/2023168,300 shares $109,395.00 +14.1%0.5%3.2 $0.65625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here 2/15/2023147,500 shares $97,792.50 -2.8%0.5%2.7 $0.66 1/31/2023151,700 shares $103,064.98 +3.1%0.5%2.3 $0.68 1/15/2023147,100 shares $109,427.69 -14.4%0.5%2.1 $0.74 12/30/2022171,800 shares $101,344.82 -14.4%0.6%2.5 $0.59 12/15/2022200,700 shares $184,684.14 -6.1%0.7%2.8 $0.92 11/30/2022213,700 shares $230,796.00 -11.1%0.8%2.8 $1.08 11/15/2022240,300 shares $254,718.00 +8.2%0.9%3.1 $1.06 10/31/2022222,200 shares $199,980.00 -15.3%0.8%3.1 $0.90 10/15/2022262,400 shares $208,634.24 +7.7%0.9%3.8 $0.80 9/30/2022243,600 shares $170,763.60 +22.8%0.9%3.6 $0.70 9/15/2022198,300 shares $164,589.00 -22.1%0.7%3.6 $0.83 8/31/2022254,600 shares $178,245.46 +6.3%1.0%4.5 $0.70 8/15/2022239,500 shares $287,400.00 -6.4%0.9%4.9 $1.20 7/31/2022255,900 shares $276,372.00 -3.4%1.0%5.3 $1.08 7/15/2022265,000 shares $315,350.00 -8.8%1.0%5.7 $1.19 6/30/2022290,700 shares $421,515.00 +17.1%1.1%4.5 $1.45 6/15/2022248,300 shares $330,239.00 -19.8%1.0%1.2 $1.33 5/31/2022309,600 shares $606,816.00 +19.8%1.2%1.5 $1.96 5/15/2022258,500 shares $514,415.00 -2.5%1.1%1.1 $1.99 4/30/2022265,100 shares $662,750.00 +3.7%1.1%1.2 $2.50 4/15/2022255,700 shares $736,416.00 -12.8%1.0%1.1 $2.88 3/31/2022293,200 shares $1.10 million -6.7%1.2%1.3 $3.76 3/15/2022314,400 shares $572,208.00 -30.0%1.3%2.9 $1.82 2/28/2022449,000 shares $2.23 million -5.9%1.8%2.7 $4.96 2/15/2022477,000 shares $2.57 million -0.1%1.9%2.3 $5.39 1/31/2022477,400 shares $2.77 million +19.7%1.9%1.9 $5.81 1/15/2022398,700 shares $2.69 million -26.9%1.6%1 $6.75 12/31/2021545,400 shares $4.26 million No Change2.2%0.8 $7.81 SABS Short Interest - Frequently Asked Questions What is SAB Biotherapeutics' current short interest? Short interest is the volume of SAB Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of October 15th, traders have sold 79,800 shares of SABS short. 1.07% of SAB Biotherapeutics' shares are currently sold short. Learn More on SAB Biotherapeutics' current short interest. What is a good short interest ratio for SAB Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SABS shares currently have a short interest ratio of 2.0. Learn More on SAB Biotherapeutics's short interest ratio. What is a good short interest percentage for SAB Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.07% of SAB Biotherapeutics' floating shares are currently sold short. Is SAB Biotherapeutics' short interest increasing or decreasing? SAB Biotherapeutics saw a increase in short interest in October. As of October 15th, there was short interest totaling 79,800 shares, an increase of 92.3% from the previous total of 41,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is SAB Biotherapeutics' float size? SAB Biotherapeutics currently has issued a total of 9,230,000 shares. Some of SAB Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. SAB Biotherapeutics currently has a public float of 7,490,000 shares. How does SAB Biotherapeutics' short interest compare to its competitors? 1.07% of SAB Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to SAB Biotherapeutics: Regulus Therapeutics Inc. (4.73%), Agenus Inc. (14.71%), Fortress Biotech, Inc. (11.74%), Curis, Inc. (1.81%), Bolt Biotherapeutics, Inc. (0.46%), Molecular Templates, Inc. (4.62%), Amgen Inc. (1.75%), Vertex Pharmaceuticals Incorporated (1.67%), Gilead Sciences, Inc. (1.33%), Regeneron Pharmaceuticals, Inc. (1.56%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks. What does it mean to sell short SAB Biotherapeutics stock? Short selling SABS is an investing strategy that aims to generate trading profit from SAB Biotherapeutics as its price is falling. SABS shares are trading up $0.62 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against SAB Biotherapeutics? A short squeeze for SAB Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SABS, which in turn drives the price of the stock up even further. How often is SAB Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SABS, twice per month. The most recent reporting period available is October, 15 2024. More Short Interest Resources from MarketBeat Related Companies Regulus Therapeutics Short Interest Data Agenus Short Interest Data Fortress Biotech Short Interest Data Curis Short Interest Data Bolt Biotherapeutics Short Interest Data Molecular Templates Short Interest Data Amgen Short Interest Data Vertex Pharmaceuticals Short Interest Data Gilead Sciences Short Interest Data Regeneron Pharmaceuticals Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SABS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
